+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA Therapy Market - Global Forecast 2026-2032- Product Image
RNA Therapy Market - Global Forecast 2026-2032- Product Image
Sale

RNA Therapy Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968964
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The RNA Therapy Market is projected to reach USD 13.71 Billion in 2026. It is expected to continue growing at a CAGR of 8.71%, reaching USD 22.68 Billion by 2032.

RNA therapy has moved from a specialized scientific platform into a core modality for modern biopharmaceutical development. The field spans messenger RNA therapeutics, small interfering RNA drugs, antisense oligonucleotides, RNA interference therapies, aptamers, and guide RNA-enabled gene editing approaches. Validated approvals, including nusinersen for spinal muscular atrophy, patisiran for hereditary transthyretin-mediated amyloidosis, inclisiran for LDL-C reduction, and mRNA vaccines for COVID-19, demonstrate that RNA-based medicines can deliver clinically meaningful outcomes across rare diseases, infectious diseases, cardiometabolic disorders, and oncology.

The RNA therapy market is being shaped by advances in lipid nanoparticles, GalNAc conjugation, chemically modified nucleotides, scalable synthesis, and improved analytical characterization. Industry attention is increasingly focused on delivery beyond the liver, durability of response, repeat dosing safety, cold-chain optimization, and regulatory readiness for platform-based product families. For decision-makers, RNA therapeutics represent both a high-growth innovation segment and a complex operating environment requiring disciplined evidence generation, manufacturing resilience, and differentiated clinical strategy.

Transformative Shifts in the RNA Therapy Landscape

The RNA therapy landscape is undergoing a structural shift from single-product innovation toward programmable medicine platforms. The success of mRNA vaccines accelerated investment in RNA design, formulation, and manufacturing infrastructure, while approved siRNA and antisense therapies validated chronic and rare disease applications. Developers are now expanding from hepatic targets into muscle, central nervous system, lung, immune, and tumor microenvironment delivery, where tissue specificity remains a central competitive differentiator.

Another major shift is the convergence of RNA therapeutics with precision medicine. Biomarker-defined populations, genetic diagnostics, newborn screening, and companion testing are improving patient identification for RNA-based interventions. At the same time, regulatory agencies are increasingly familiar with oligonucleotide chemistry, platform comparability, and manufacturing controls, creating a more mature path for developers that can demonstrate quality, safety, and reproducible clinical benefit.

Cumulative Impact of Artificial Intelligence on RNA Therapy

Artificial intelligence is increasingly influencing RNA therapy discovery, design, and development. AI-enabled models support target prioritization, off-target risk assessment, sequence optimization, codon usage design, immune-stimulation prediction, and lipid nanoparticle formulation screening. The FDA has reported a sharp rise in drug and biologic submissions containing AI or machine learning components, signaling that computational approaches are becoming embedded in regulated development workflows.

The cumulative impact of AI is most visible in cycle-time compression and experiment prioritization rather than in replacing biological validation. For RNA therapeutics, AI can help narrow candidate libraries, improve manufacturability, identify toxicity signals earlier, and integrate multi-omics evidence for patient stratification. Industry leaders that combine AI with high-quality wet-lab data, traceable model governance, and regulatory documentation are better positioned to improve probability of success while maintaining scientific credibility.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a leading hub for RNA therapy innovation, supported by the United States biotechnology ecosystem, FDA experience with mRNA vaccines, siRNA drugs, antisense oligonucleotides, and advanced therapy regulatory pathways. Canada contributes through academic research, clinical trial participation, public genomics initiatives, and health system infrastructure, while Mexico is increasingly relevant for regional healthcare access discussions, clinical operations, and cross-border supply-chain planning.

Europe benefits from the European Medicines Agency, the Horizon Europe research framework, national genomics strategies, and strong biomanufacturing clusters across Germany, France, the United Kingdom, Italy, and Spain. Asia-Pacific is expanding through China’s large clinical trial base, Japan’s mature regulatory and pharmaceutical environment, South Korea’s biologics manufacturing strength, India’s cost-efficient scientific talent and vaccine production experience, and Australia’s active early-stage clinical research incentives. Latin America, led by Brazil and Mexico, is gaining attention for infectious disease experience, diverse patient recruitment, and public health networks, while the Middle East and Africa are emerging through vaccine access programs, genomics initiatives, healthcare modernization, and gradual investments in local biomanufacturing capacity.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN countries are building relevance in RNA therapy through expanding clinical research networks, vaccine manufacturing ambitions, and public health preparedness programs. Singapore plays a regional role in biomedical R&D and advanced manufacturing, while Thailand, Malaysia, Indonesia, the Philippines, and Vietnam offer growing patient access and trial-enrollment potential when regulatory alignment, pharmacovigilance, reimbursement readiness, and cold-chain capacity are addressed.

The European Union provides harmonized regulatory pathways, cross-border research funding, data protection rules, and strong intellectual property structures that support RNA therapeutic development. GCC countries are investing in precision medicine, genomics, tertiary care, and pharmaceutical localization as part of economic diversification strategies. BRICS nations are important for scientific and patient scale, with China and India offering large research and manufacturing bases, Brazil and South Africa contributing regional access and public health perspectives, and Russia maintaining scientific capacity amid external constraints. G7 markets remain central to premium reimbursement, advanced clinical adoption, regulatory precedent, and post-approval evidence generation, while NATO member countries overlap substantially with high-income biopharma markets and resilient medical supply-chain priorities.

Key Country Insights for RNA Therapy Growth

The United States leads RNA therapy commercialization through deep venture capital markets, FDA-approved RNA medicines, advanced clinical trial infrastructure, and a dense network of biotech developers, contract manufacturers, and academic centers. Canada supports translational research, genomics, and clinical collaboration, while Mexico is an important North American market for patient access and regional healthcare partnerships. Brazil anchors Latin America with a large population, established clinical research capacity, and public health experience relevant to vaccine and infectious disease platforms.

In Europe, the United Kingdom, Germany, and France are prominent in RNA research, regulatory science, and pharmaceutical development, while Italy and Spain strengthen clinical trial networks, specialist hospitals, and hospital-based adoption. Russia maintains scientific expertise but faces geopolitical, regulatory, and supply-chain constraints. In Asia-Pacific, China is scaling RNA research, clinical development, and manufacturing; India offers scientific talent, vaccine infrastructure, and cost-efficient production potential; Japan provides mature regulatory and pharmaceutical capabilities; Australia is recognized for early-phase clinical research and favorable trial operations; and South Korea is advancing biologics manufacturing, vaccine platforms, and global CDMO relevance.

Actionable Recommendations for RNA Therapy Industry Leaders

Industry leaders should prioritize delivery innovation, because tissue targeting remains the most important technical constraint for RNA therapy expansion beyond liver-directed programs. Investment in lipid nanoparticle engineering, ligand conjugation, endosomal escape technologies, and local delivery approaches should be paired with rigorous safety pharmacology, biodistribution studies, immunogenicity assessment, and repeat-dose monitoring.

Organizations should also strengthen CMC strategy early. Scalable oligonucleotide synthesis, impurity control, analytical comparability, sterile fill-finish capacity, raw material security, and cold-chain resilience can determine development timelines as much as clinical efficacy. Organizations should build regulatory engagement plans that address platform data, immunogenicity, repeat dosing, pharmacovigilance, and long-term follow-up. Partnerships with diagnostics providers, AI-enabled discovery platforms, CDMOs, and regional clinical networks can accelerate development while reducing risk.

Research Methodology

This executive summary is developed through secondary research and expert synthesis of publicly available, verifiable sources, including regulatory approvals and guidance from the FDA and EMA, clinical trial registries, peer-reviewed literature, public health agency updates, patent databases, and recognized biotechnology industry disclosures. The analysis emphasizes confirmed product approvals, documented platform advances, regional policy signals, and observable investment and manufacturing trends.

The methodology applies triangulation across regulatory, scientific, commercial, and geographic datasets to identify durable market patterns rather than speculative claims. Each insight is assessed for relevance to RNA therapeutics, including mRNA therapy, siRNA drugs, antisense oligonucleotides, RNA interference, delivery systems, GMP manufacturing, clinical adoption, and regional access dynamics. The resulting perspective is designed to support planning, market positioning, and digital communication.

Conclusion

RNA therapy is now an established and expanding therapeutic category, supported by approved medicines, validated delivery technologies, and increasing regulatory familiarity. The sector’s next phase will depend on expanding delivery to new tissues, improving durability and tolerability, reducing manufacturing complexity, and demonstrating value in large and genetically defined patient populations.

Organizations that combine strong science, platform governance, AI-enabled development, regional access planning, and manufacturing excellence will be best positioned to compete. As RNA therapeutics continue to reshape rare disease, infectious disease, oncology, neurology, and cardiometabolic care, the market offers substantial opportunity for developers capable of converting programmable biology into reliable, accessible, and clinically differentiated medicines.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. RNA Therapy Market, by RNA Type
7.1. Introduction
7.2. Messenger RNA
7.2.1. Circular mRNA
7.2.2. Conventional mRNA
7.3. Small Interfering RNA
7.3.1. Unmodified siRNA
7.3.2. Chemically Modified siRNA
7.4. Antisense Oligonucleotides
7.5. MicroRNA
7.6. Ribozymes
8. RNA Therapy Market, by Delivery System
8.1. Introduction
8.2. Exosomes
8.3. Lipid Nanoparticles
8.4. Polymer Carriers
8.5. Viral Vectors
9. RNA Therapy Market, by Therapeutic Modality
9.1. Introduction
9.2. Gene Silencing
9.3. Gene Replacement
9.4. Protein Expression Induction
9.5. Splicing Modulation
9.6. Immune System Modulation
10. RNA Therapy Market, by Application Area
10.1. Introduction
10.2. Cardiovascular Diseases
10.3. Genetic Disorders
10.4. Infectious Diseases
10.4.1. Bacterial Infections
10.4.2. Viral Infections
10.5. Metabolic Disorders
10.6. Neurological Disorders
10.7. Oncology
10.7.1. Hematological Malignancies
10.7.2. Solid Tumors
10.8. Rare Diseases
10.8.1. Gaucher Disease
10.8.2. Neuromuscular Disorders
10.8.3. Sickle Cell Disease
11. RNA Therapy Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.3. Hospitals & Clinics
11.4. Pharmaceutical Companies
11.5. Research Institutes
12. RNA Therapy Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. RNA Therapy Market, by Group
13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC
14. RNA Therapy Market, by Country
14.1. United States
14.2. China
14.3. Germany
14.4. Japan
14.5. India
14.6. United Kingdom
14.7. France
14.8. Canada
14.9. Italy
14.10. Australia
14.11. South Korea
14.12. Brazil
14.13. Mexico
14.14. Russia
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alnylam Pharmaceuticals, Inc.
16.2. Arbutus Biopharma Corporation
16.3. Arrowhead Pharmaceuticals, Inc.
16.4. AstraZeneca PLC
16.5. Benitec Biopharma Limited
16.6. Biogen Inc.
16.7. BioNTech SE
16.8. Cartesian Therapeutics, Inc.
16.9. Cenix BioScience GmbH
16.10. Deep Genomics
16.11. Eli Lilly and Company
16.12. F. Hoffmann-La Roche Ltd
16.13. GSK PLC
16.14. Ionis Pharmaceuticals, Inc.
16.15. MiNA Therapeutics Limited
16.16. Moderna, Inc.
16.17. NeuBase Therapeutics, Inc.
16.18. Nordic Nanovector ASA
16.19. Novartis AG
16.20. Novo Nordisk A/S
16.21. Nutcracker Therapeutics, Inc.
16.22. Pfizer Inc.
16.23. ProQR Therapeutics N.V.
16.24. Sanofi S.A.
16.25. Silence Therapeutics PLC
16.26. Sirnaomics, Inc.
16.27. Suzhou Abogen Biosciences Co., Ltd.
16.28. Triplet Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL RNA THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RNA THERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RNA THERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RNA THERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL RNA THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RNA THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL MESSENGER RNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL MESSENGER RNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL MESSENGER RNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CIRCULAR MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CIRCULAR MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CIRCULAR MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SMALL INTERFERING RNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SMALL INTERFERING RNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SMALL INTERFERING RNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL UNMODIFIED SIRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL UNMODIFIED SIRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL UNMODIFIED SIRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CHEMICALLY MODIFIED SIRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CHEMICALLY MODIFIED SIRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CHEMICALLY MODIFIED SIRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MICRORNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RIBOZYMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL RIBOZYMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL RIBOZYMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL POLYMER CARRIERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL POLYMER CARRIERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POLYMER CARRIERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL GENE SILENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL GENE SILENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL GENE SILENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL GENE REPLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL GENE REPLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL GENE REPLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PROTEIN EXPRESSION INDUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PROTEIN EXPRESSION INDUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PROTEIN EXPRESSION INDUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SPLICING MODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL SPLICING MODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SPLICING MODULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL GAUCHER DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL GAUCHER DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 128. EUROPE RNA THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. EUROPE RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 130. EUROPE RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 131. EUROPE RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 132. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 133. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 134. EUROPE RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 135. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 136. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 137. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 138. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. AFRICA RNA THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. AFRICA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 163. AFRICA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 164. AFRICA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 165. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 166. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 167. AFRICA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 168. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 169. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 170. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 171. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST RNA THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 184. NATO RNA THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. NATO RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 186. NATO RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 187. NATO RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 188. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 189. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 190. NATO RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 191. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 192. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 193. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 194. NATO RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 195. G7 RNA THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. G7 RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 197. G7 RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 198. G7 RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 199. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 200. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 201. G7 RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 202. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 203. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 204. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 205. G7 RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. BRICS RNA THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. BRICS RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 219. BRICS RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 220. BRICS RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 221. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 222. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 223. BRICS RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 224. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 225. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 226. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 227. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. ASEAN RNA THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. ASEAN RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 230. ASEAN RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 231. ASEAN RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 232. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 233. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 234. ASEAN RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 235. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 236. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 237. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 238. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. GCC RNA THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 240. GCC RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 241. GCC RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 242. GCC RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 243. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 244. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 245. GCC RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 246. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 247. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 248. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 249. GCC RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 251. UNITED STATES RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 253. UNITED STATES RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 254. UNITED STATES RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 255. UNITED STATES RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 256. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 257. UNITED STATES RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 258. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 259. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 260. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 261. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. CHINA RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. CHINA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 264. CHINA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 265. CHINA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 266. CHINA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 267. CHINA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 268. CHINA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 269. CHINA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 270. CHINA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 271. CHINA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 272. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. GERMANY RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. GERMANY RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 275. GERMANY RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 276. GERMANY RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 277. GERMANY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 278. GERMANY RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 279. GERMANY RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 280. GERMANY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 281. GERMANY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 282. GERMANY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 283. GERMANY RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. JAPAN RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 285. JAPAN RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 286. JAPAN RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 287. JAPAN RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 288. JAPAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 289. JAPAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 290. JAPAN RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 291. JAPAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 292. JAPAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 293. JAPAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 294. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. INDIA RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. INDIA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 297. INDIA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 298. INDIA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 299. INDIA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 300. INDIA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 301. INDIA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 302. INDIA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 303. INDIA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 304. INDIA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 305. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. FRANCE RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. FRANCE RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 319. FRANCE RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 320. FRANCE RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 321. FRANCE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 322. FRANCE RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 323. FRANCE RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 324. FRANCE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 325. FRANCE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 326. FRANCE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 327. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. CANADA RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 329. CANADA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 330. CANADA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 331. CANADA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 332. CANADA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 333. CANADA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 334. CANADA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 335. CANADA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 336. CANADA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 337. CANADA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 338. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. ITALY RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. ITALY RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 341. ITALY RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 342. ITALY RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 343. ITALY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 344. ITALY RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 345. ITALY RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 346. ITALY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 347. ITALY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 348. ITALY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 349. ITALY RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 354. AUSTRALIA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 355. AUSTRALIA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 356. AUSTRALIA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 357. AUSTRALIA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 358. AUSTRALIA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 359. AUSTRALIA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 360. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 362. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 363. SOUTH KOREA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 364. SOUTH KOREA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 365. SOUTH KOREA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 366. SOUTH KOREA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 367. SOUTH KOREA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 368. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 369. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 370. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 371. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 372. BRAZIL RNA THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 373. BRAZIL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2017-2032 (USD MILLION)
TABLE 374. BRAZIL RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2017-2032 (USD MILLION)
TABLE 375. BRAZIL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2017-2032 (USD MILLION)
TABLE 376. BRAZIL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2017-2032 (USD MILLION)
TABLE 377. BRAZIL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 378. BRAZIL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2017-2032 (USD MILLION)
TABLE 379. BRAZIL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 380. BRAZIL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 381. BRAZIL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 382. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 383. MEXICO RNA THERAPY MARKET SIZE, 2017-2032 (USD MILL

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Benitec Biopharma Limited
  • Biogen Inc.
  • BioNTech SE
  • Cartesian Therapeutics, Inc.
  • Cenix BioScience GmbH
  • Deep Genomics
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • MiNA Therapeutics Limited
  • Moderna, Inc.
  • NeuBase Therapeutics, Inc.
  • Nordic Nanovector ASA
  • Novartis AG
  • Novo Nordisk A/S
  • Nutcracker Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics N.V.
  • Sanofi S.A.
  • Silence Therapeutics PLC
  • Sirnaomics, Inc.
  • Suzhou Abogen Biosciences Co., Ltd.
  • Triplet Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.71 Billion
Forecasted Market Value ( USD ) by 2032 $ 22.68 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026 - Product Image

Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026

  • Report
  • 250 Pages
  • Global
From
RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
RNA-based Therapeutics - Global Strategic Business Report - Product Image

RNA-based Therapeutics - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
RNA Therapy Clinical Trials Market - Global Strategic Business Report - Product Image

RNA Therapy Clinical Trials Market - Global Strategic Business Report

  • Report
  • 244 Pages
  • Global
From
Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing - Product Image

Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

  • Report
  • 166 Pages
  • Global
From

About the RNA Therapy Market

RNA therapy is a form of gene therapy that uses RNA molecules to treat or prevent diseases. It is a type of genomics-based therapy that works by introducing genetic material into cells to modify their behavior. RNA therapy can be used to treat a variety of diseases, including cancer, neurological disorders, and infectious diseases. It has the potential to be used to treat genetic disorders, as well as to modify the expression of genes in order to improve the effectiveness of existing treatments. RNA therapy works by introducing genetic material into cells, which can then be used to modify the expression of genes. This can be done by introducing a gene that produces a therapeutic protein, or by introducing a gene that silences a gene that is causing a disease. RNA therapy can also be used to modify the expression of existing genes, which can be used to improve the effectiveness of existing treatments. RNA therapy is an emerging field of genomics-based therapy, and is being explored by a number of companies. Examples of companies in the RNA therapy market include Moderna, BioNTech, and Arcturus Therapeutics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.